Research Team (MDPMC Phase II)
Dr. Rima Kaddurah-Daouk, PhD.
Duke University
Professor in the Departments of Psychiatry and Medicine at Duke University Medical Center. She made seminal contributions to the development of the metabolomics field. She established and leads several large consortia including the Mood Disorders Precision Medicine Consortium, the Alzheimer’s Disease Metabolomics Consortium (ADMC) and the Alzheimer's Gut Microbiome Project (AGMP).
Dr. Boadie Dunlop, MD, MS
Emory University
Boadie Dunlop, MD, MSCR, has served as the Director of the Mood and Anxiety Disorders Program (MAP) at Emory University since 2006. He graduated from Mayo Medical School in 1997 and completed his Residency in Psychiatry at Emory in 2001. His clinical research is focused on the neurobiology, psychopharmacology and treatment of major depression, bipolar disorder, and anxiety disorders.
Research Team Members
Dr. Augustus John Rush, MD
Duke University
Augustus John Rush is an internationally renowned psychiatrist. He is a Professor Emeritus in Duke-NUS Medical School at the National University of Singapore, and Adjunct Professor of Psychiatry and Behavioral Sciences at Duke University School of Medicine.
Dr. W. Edward Craighead, PhD
Emory University
Dr. Craighead’s research, which focuses on mood disorders, has been funded for several years by NIMH and private Foundations. Over the past three decades, his work has focused on cognitive behavioral models of Major Depression and Bipolar Disorders.
Dr. Brenda Peninnx, MD
Amsterdam University Medical Center
Brenda Penninx, PhD, is professor of psychiatric epidemiology at the department of Psychiatry of Amsterdam UMC (location VUmc) in Amsterdam (https://psychiatryamsterdam.nl). Since 2004 she leads the Netherlands Study of Depression and Anxiety (NESDA: www.nesda.nl), a longitudinal study of the course and consequences of depressive and anxiety disorders.
Dr. Helen Mayberg, MD
Icahn School of Medicine at Mount Sinai
Dr. Mayberg leads a multidisciplinary research program committed to defining the “neurology of depression.” Her imaging studies over the past 20 years have systematically examined functional abnormalities characterizing the disorder, as well as neural mechanisms mediating antidepressant response to various evidence-based treatments.
Dr. Elizabeth Binder, PhD
Max Planck Institute of Psychiatry
Assistant Professor of Depts. of Psychiatry and Behavioral Sciences and Human Genetics, Emory University School of Medicine. Since 2007 Research group leader at the Max-Planck Institute of Psychiatry. Director and Scientific Member at the Max Planck Institute of Psychiatry as of August 2013.
Dr. Gabi Kastenmüller, PhD
Helmholtz Zentrum München
Director (acting) of the Institute of Bioinformatics and Systems Biology (IBIS), Helmholtz
Zentrum München. Her group studies human chemical individuality and its effects in health, disease, and treatment, metabolome-wide and genome-wide associations, and creates nioinformatic tools and databases for metabolomics data analysis and data interpretation
Dr. Matthias Arnold, PhD
Helmholtz Zentrum München
Lead analyst on metabolomics projects at the Helmholtz Zentrum München. Dr. Arnold specializes in metabolomics as well as the integration with multi-omics into networks. As lead analyst he is involved in the QC and analysis of metabolomic datasets and consults on the analysis plans of other analysts across multiple metabolomics consortia.
Dr. Alejo Nevado-Helgado, PhD
University of Oxford
Dr. Nevado-Helgado leads the AI team in the TNDR (https://www.psych.ox.ac.uk/research/dementia-research-group) laboratory in the Department of Psychiatry, formed by 10 excellent machine learners and bioinformaticians. Their focus is on the applications of machine learning and bioinformatics to mental health care. He is collaborating with the MDPMC for the application of machine learning to metabolomics-genomics for novel insights into MDD.

Colette Blach
Duke University
Colette Blach is the MDPMC data manager. Her role is critical for all processes involving organizing and distributing raw datasets for quality control to fully vetted, versioned and locked datasets to consortium members and to the public in a timely manner.
Dr. Sudeepa Bhattacharyya, PhD.
Arkansas State University
Dr. Sudeepa Bhattacharyya combines deep knowledge of both biochemical pathways and advanced statistical methods. For the past four years she has worked with the MDPMC to analyze and publish our findings on the MDPMC metabolomics datasets.
Dr. Yuri Milaneschi, PhD
Amsterdam University Medical Center
Dr. Yuri Milaneschi is assistant professor at GGZ inGeest and the department of psychiatry Amsterdam UMC/VUmc. After studies and training in clinical psychology in Italy, Yuri Milaneschi (1978) worked in the field of epidemiology of aging in Italy (2007-2010) and the USA (National Institute of Aging, 2010-2012). He combined these two perspectives in his major research theme: the study, using the tools of epidemiology, of biological pathways that may have a role in the pathophysiology of depression.
Dr. Janine Knauer-Arloth
Max Planck Institute of Psychiatry
Dr. Knauer-Arloth is the Project Group Leader in the Dept. Translational Research in Psychiatry at the Max Planck Institute of Psychiatry.
Dr. Dennis Mook-Kanamori, MD
Leiden University
Dr. Dennis Mook-Kanamori, MD works at theDepartment of Clinical Epidemiology and Primary Care at the Leiden University Medical Centre. He coordinates the genetic studies in the NEO (Netherlands Epidemiology of Obesity). His current research focuses on metabolomic, genetic and environmental markers of complex traits.
Dr. Xianlin Han, PhD
University of Texas Health Sciences Center, San Antonio
Dr. Xianlin Han is an internationally-renowned investigator in the fields of lipidomics, lipid metabolism, and lipid biochemistry working at the University of Texas Health Sciences Center in San Antonio. He has developed expertise in broad areas of research, such as diabetes, neuroscience, and metabolic biochemistry. His current research focuses on diabetic neuropathy, mitochondrial dysfunction in diabetic hearts, Alzheimer’s disease and mood disorders, such as depression. He serves as a lipidomics expert consultant with the MDPMC.
Dr. Piero Rinaldo, MD, PhD
Mayo Clinic
Dr. Rinaldo is currently interested in the clinical implementation of multivariate pattern recognition software that improves the interpretation of complex profiles of laboratory results. The goal is to integrate all clinically significant results available to diagnose a particular condition in a single score in a manner that is objective, evidence-based, and open to worldwide collaboration and data sharing. He is consulting with the MDPMC to apply these same techniques with metablomics data.